Johannes-Peter Stasch

List of Publications by Year
in descending order

145	9,133	31976	42399
papers	citations	53 h-index	92 g-index

151	151	151	6080
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nature Reviews Drug Discovery, 2006, 5, 755-768.	46.4	623
2	NO-independent regulatory site on soluble guanylate cyclase. Nature, 2001, 410, 212-215.	27.8	512
3	Soluble Guanylate Cyclase as an Emerging Therapeutic Target in Cardiopulmonary Disease. Circulation, 2011, 123, 2263-2273.	1.6	483
4	Kynurenine is an endothelium-derived relaxing factor produced during inflammation. Nature Medicine, 2010, 16, 279-285.	30.7	418
5	Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. Journal of Clinical Investigation, 2006, 116, 2552-2561.	8.2	390
6	NOâ€•and haemâ€‘independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle. British Journal of Pharmacology, 2002, 136, 773-783.	5.4	268
7	Activation of Soluble Guanylate Cyclase Reverses Experimental Pulmonary Hypertension and Vascular Remodeling. Circulation, 2006, 113, 286-295.	1.6	208
8	Effect of YCâ€‘1, an NOâ€‘independent, superoxideâ€‘sensitive stimulator of soluble guanylyl cyclase, on smooth muscle responsiveness to nitrovasodilators. British Journal of Pharmacology, 1997, 120, 681-689.	5.4	206
9	The Chemistry and Biology of Soluble Guanylate Cyclase Stimulators and Activators. Angewandte Chemie - International Edition, 2013, 52, 9442-9462.	13.8	173
10	NO-Independent, Haem-Dependent Soluble Guanylate Cyclase Stimulators. Handbook of Experimental Pharmacology, 2009, , 277-308.	1.8	171
11	Discovery of Riociguat (BAY 63â€‘2521): A Potent, Oral Stimulator of Soluble Guanylate Cyclase for the Treatment of Pulmonary Hypertension. ChemMedChem, 2009, 4, 853-865.	3.2	162
12	Identification of Residues Crucially Involved in the Binding of the Heme Moiety of Soluble Guanylate Cyclase. Journal of Biological Chemistry, 2004, 279, 3025-3032.	3.4	145
13	NO-Independent stimulators of soluble guanylate cyclase. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 781-784.	2.2	144
14	Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart Failure. Journal of Medicinal Chemistry, 2017, 60, 5146-5161.	6.4	133
15	Effects of In Vivo Nitroglycerin Treatment on Activity and Expression of the Guanylyl Cyclase and cGMP-Dependent Protein Kinase and Their Downstream Target Vasodilator-Stimulated Phosphoprotein in Aorta. Circulation, 2001, 103, 2188-2194.	1.6	132
16	NO- and Haem-Independent Soluble Guanylate Cyclase Activators. Handbook of Experimental Pharmacology, 2009, , 309-339.	1.8	131
17	The cGMP Signaling Pathway as a Therapeutic Target in Heart Failure With Preserved Ejection Fraction. Journal of the American Heart Association, 2013, 2, e000536.	3.7	131
18	Pharmacological actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vitro studies. British Journal of Pharmacology, 2002, 135, 333-343.	5.4	121

#	Article	IF	Citations
19	Soluble guanylate cyclase: a potential therapeutic target for heart failure. Heart Failure Reviews, 2013, 18, 123-134.	3.9	118
20	Soluble Guanylate Cyclase Stimulators in Pulmonary Hypertension. Handbook of Experimental Pharmacology, 2013, , 279-313.	1.8	118
21	Purified soluble guanylyl cyclase expressed in a baculovirus/Sf9 system: stimulation by YC-1, nitric oxide, and carbon monoxide. Journal of Molecular Medicine, 1999, 77, 14-23.	3.9	117
22	Cardiovascular actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vivo studies. British Journal of Pharmacology, 2002, 135, 344-355.	5.4	105
23	Soluble Guanylate Cyclase Stimulators and Activators. Handbook of Experimental Pharmacology, 2018, 264, 355-394.	1.8	104
24	The Soluble Guanylate Cyclase Stimulator Riociguat Ameliorates Pulmonary Hypertension Induced by Hypoxia and SU5416 in Rats. PLoS ONE, 2012, 7, e43433.	2.5	100
25	Cardiorenal and Humoral Properties of a Novel Direct Soluble Guanylate Cyclase Stimulator BAY 41-2272 in Experimental Congestive Heart Failure. Circulation, 2003, 107, 686-689.	1.6	98
26	Nitric Oxideâ€“Independent Vasodilator Rescues Heme-Oxidized Soluble Guanylate Cyclase From Proteasomal Degradation. Circulation Research, 2009, 105, 33-41.	4.5	98
27	Renal effects of soluble guanylate cyclase stimulators and activators: A review of the preclinical evidence. Current Opinion in Pharmacology, 2015, 21, 95-104.	3.5	93
28	Targeting Heme-Oxidized Soluble Guanylate Cyclase in Experimental Heart Failure. Hypertension, 2007, 49, 1128-1133.	2.7	91
29	Structure of Cinaciguat (BAY 58â€“2667) Bound to Nostoc H-NOX Domain Reveals Insights into Heme-mimetic Activation of the Soluble Guanylyl Cyclase. Journal of Biological Chemistry, 2010, 285, 22651-22657.	3.4	90
30	Soluble Guanylate Cyclase Stimulation Prevents Fibrotic Tissue Remodeling and Improves Survival in Salt-Sensitive Dahl Rats. PLoS ONE, 2011, 6, e21853.	2.5	88
31	Mechanisms of nitric oxide independent activation of soluble guanylyl cyclase. European Journal of Pharmacology, 2003, 468, 167-174.	3.5	85
32	Stimulation of soluble guanylyl cyclase protects against obesity by recruiting brown adipose tissue. Nature Communications, 2015, 6, 7235.	12.8	85
33	Singlet molecular oxygen regulates vascular tone and blood pressure in inflammation. Nature, 2019, 566, 548-552.	27.8	84
34	Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experimental low-renin and high-renin models. Journal of Hypertension, 2010, 28, 1666-1675.	0.5	82
35	Cinaciguat, a soluble guanylate cyclase activator, augments cGMP after oxidative stress and causes pulmonary vasodilation in neonatal pulmonary hypertension. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2011, 301, L755-L764.	2.9	82
36	Riociguat for the treatment of pulmonary hypertension. Expert Opinion on Investigational Drugs, 2011, 20, 567-576.	4.1	81

#	Article	IF	Citations
37	Stimulation of Soluble Guanylate Cyclase Prevents Cigarette Smokeâ€“induced Pulmonary Hypertension and Emphysema. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 1359-1373.	5.6	80
38	Soluble Guanylate Cyclase Stimulators in Pulmonary Hypertension. Handbook of Experimental Pharmacology, 2013, 218, 279-313.	1.8	80
39	Nucleotidyl Cyclase Activity of Soluble Guanylyl Cyclase Î±₁Î²₁. Biochemistry, 2012, 51, 194-204.	2.5	79
40	Riociguat: Mode of Action and Clinical Development in Pulmonary Hypertension. Chest, 2017, 151, 468-480.	0.8	79
41	Inhaled Agonists of Soluble Guanylate Cyclase Induce Selective Pulmonary Vasodilation. American Journal of Respiratory and Critical Care Medicine, 2007, 176, 1138-1145.	5.6	74
42	Pressure-independent effects of pharmacological stimulation of soluble guanylate cyclase on fibrosis in pressure-overloaded rat heart. Hypertension Research, 2009, 32, 597-603.	2.7	73
43	Nitric Oxide-independent Activation of Soluble Guanylate Cyclase by BAY 60-2770 in Experimental Liver Fibrosis. Arzneimittelforschung, 2008, 58, 71-80.	0.4	71
44	NOâ€independent activation of soluble guanylate cyclase prevents disease progression in rats with 5/6 nephrectomy. British Journal of Pharmacology, 2006, 148, 853-859.	5.4	66
45	Soluble Guanylate Cyclase Stimulation on Cardiovascular Remodeling in Angiotensin Iiâ€“Induced Hypertensive Rats. Hypertension, 2006, 48, 972-978.	2.7	65
46	Cardiovascular and pharmacological implications of haem-deficient NO-unresponsive soluble guanylate cyclase knock-in mice. Nature Communications, 2015, 6, 8482.	12.8	64
47	4-Phenyl-4H-pyrans as IKCa channel blockers. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 2637-2639.	2.2	62
48	Cinaciguat, a novel activator of soluble guanylate cyclase, protects against ischemia/reperfusion injury: role of hydrogen sulfide. American Journal of Physiology - Heart and Circulatory Physiology, 2012, 302, H1347-H1354.	3.2	62
49	Nitric Oxide and Heat Shock Protein 90 Activate Soluble Guanylate Cyclase by Driving Rapid Change in Its Subunit Interactions and Heme Content. Journal of Biological Chemistry, 2014, 289, 15259-15271.	3.4	62
50	Metabolites of Orally Active NO-Independent Pyrazolopyridine Stimulators of Soluble Guanylate Cyclase. Bioorganic and Medicinal Chemistry, 2002, 10, 1711-1717.	3.0	61
51	A cell-based cGMP assay useful for ultra-high-throughput screening and identification of modulators of the nitric oxide/cGMP pathway. Analytical Biochemistry, 2005, 339, 104-112.	2.4	61
52	Identification of a soluble guanylate cyclase in RBCs: preserved activity in patients with coronary artery disease. Redox Biology, 2018, 14, 328-337.	9.0	59
53	Pulmonary and systemic vasodilator responses to the soluble guanylyl cyclase activator, BAY 60â€“2770, are not dependent on endogenous nitric oxide or reduced heme. American Journal of Physiology - Heart and Circulatory Physiology, 2011, 300, H792-H802.	3.2	58
54	Soluble guanylate cyclase as an alternative target for bronchodilator therapy in asthma. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E2355-62.	7.1	57

#	Article	IF	Citations
55	NO-independent regulatory site of direct sGC stimulators like YC-1 and BAY 41-2272. BMC Pharmacology, 2001, 1, 13.	0.4	53
56	Insights into BAY 60-2770 Activation and S-Nitrosylation-Dependent Desensitization of Soluble Guanylyl Cyclase via Crystal Structures of Homologous Nostoc H-NOX Domain Complexes. Biochemistry, 2013, 52, 3601-3608.	2.5	52
57	The Soluble Guanylyl Cyclase Activator Bay 58-2667 Selectively Limits Cardiomyocyte Hypertrophy. PLoS ONE, 2012, 7, e44481.	2.5	50
58	Dimerization Region of Soluble Guanylate Cyclase Characterized by Bimolecular Fluorescence Complementation in Vivo. Molecular Pharmacology, 2007, 72, 1181-1190.	2.3	45
59	Soluble GC stimulators and activators: Past, present and future. British Journal of Pharmacology, 2021, , .	5.4	45
60	BAY 41-2272 Activates Two Isoforms of Nitric Oxide- Sensitive Guanylyl Cyclase. Biochemical and Biophysical Research Communications, 2002, 292, 1057-1062.	2.1	42
61	BAY 58-2667, a nitric oxide-independent guanylyl cyclase activator, pharmacologically post-conditions rabbit and rat hearts. European Heart Journal, 2009, 30, 1607-1613.	2.2	42
62	Nucleotidyl cyclase activity of soluble guanylyl cyclase in intact cells. Biochemical and Biophysical Research Communications, 2014, 443, 1195-1199.	2.1	39
63	Discovery of the Soluble Guanylate Cyclase Activator Runcaciguat (BAY 1101042). Journal of Medicinal Chemistry, 2021, 64, 5323-5344.	6.4	38
64	Riociguat Reduces Infarct Size and Post-Infarct Heart Failure in Mouse Hearts: Insights from MRI/PET Imaging. PLoS ONE, 2013, 8, e83910.	2.5	36
65	Diabetic Endothelin B Receptorâ€“Deficient Rats Develop Severe Hypertension and Progressive Renal Failure. Journal of the American Society of Nephrology: JASN, 2006, 17, 1082-1089.	6.1	34
66	Design and Synthesis of Potent and Selective Azaindoleâ€Based Rho Kinase (ROCK) Inhibitors. ChemMedChem, 2008, 3, 1893-1904.	3.2	34
67	NO-independent stimulation or activation of soluble guanylyl cyclase during early reperfusion limits infarct size. Cardiovascular Research, 2014, 101, 220-228.	3.8	34
68	The Vasodilator-Stimulated Phosphoprotein (VASP): Target of YC-1 and Nitric Oxide Effects in Human and Rat Platelets. Journal of Cardiovascular Pharmacology, 2000, 35, 390-397.	1.9	34
69	Residues stabilizing the heme moiety of the nitric oxide sensor soluble guanylate cyclase. European Journal of Pharmacology, 2005, 513, 67-74.	3.5	33
70	Effects of Stimulation of Soluble Guanylate Cyclase on Diabetic Nephropathy in Diabetic eNOS Knockout Mice on Top of Angiotensin II Receptor Blockade. PLoS ONE, 2012, 7, e42623.	2.5	31
71	The elevation of cyclic GMP as a response to acute hypervolemia is blocked by a monoclonal antibody directed against atrial natriuretic peptides. European Journal of Pharmacology, 1986, 129, 165-168.	3.5	30
72	Stimulation of soluble guanylyl cyclase inhibits mesangial cell proliferation and matrix accumulation in experimental glomerulonephritis. American Journal of Physiology - Renal Physiology, 2005, 288, F685-F693.	2.7	29

#	Article	IF	Citations
73	Identification of residues crucially involved in soluble guanylate cyclase activation. FEBS Letters, 2006, 580, 4205-4213.	2.8	29
74	Effect of Riociguat and Sildenafil on Right Heart Remodeling and Function in Pressure Overload Induced Model of Pulmonary Arterial Banding. BioMed Research International, 2018, 2018, 1-9.	1.9	29
75	Fluorescence Dequenching Makes Haem-Free Soluble Guanylate Cyclase Detectable in Living Cells. PLoS ONE, 2011, 6, e23596.	2.5	29
76	Soluble guanylate cyclase stimulator riociguat and phosphodiesterase 5 inhibitor sildenafil ameliorate pulmonary hypertension due to left heart disease in mice. International Journal of Cardiology, 2016, 216, 85-91.	1.7	28
77	Inhibition of the <scp>TGF</scp>Î² signalling pathway by <scp>cGMP</scp> and <scp>cGMP</scp>â€dependent kinase I in renal fibrosis. FEBS Open Bio, 2017, 7, 550-561.	2.3	27
78	Nitric oxideâ€“sensitive guanylyl cyclase stimulation improves experimental heart failure with preserved ejection fraction. JCI Insight, 2018, 3, .	5.0	27
79	Effects of the sGC Stimulator BAY 41-2272 Are Not Mediated by Phosphodiesterase 5 Inhibition. Circulation, 2004, 110, e320-1; author reply e320-1.	1.6	26
80	Relaxin Is an Independent Risk Factor Predicting Death in Male Patients With End-Stage Kidney Disease. Circulation, 2004, 109, 2266-2268.	1.6	26
81	Endothelin-1 overexpression restores diastolic function in eNOS knockout mice. Journal of Hypertension, 2011, 29, 961-970.	0.5	26
82	Pre-conditioning with the soluble guanylate cyclase activator Cinaciguat reduces ischaemiaâ€“reperfusion injury after cardiopulmonary bypass. European Journal of Cardio-thoracic Surgery, 2011, 39, 248-255.	1.4	26
83	Direct sGC Activation Bypasses NO Scavenging Reactions of Intravascular Free Oxy-Hemoglobin and Limits Vasoconstriction. Antioxidants and Redox Signaling, 2013, 19, 2232-2243.	5.4	26
84	Nitric Oxideâ€“Independent Soluble Guanylate Cyclase Activation Improves Vascular Function and Cardiac Remodeling in Sickle Cell Disease. American Journal of Respiratory Cell and Molecular Biology, 2018, 58, 636-647.	2.9	25
85	Different effects of ANP and nitroprusside on cyclic GMP extrusion of isolated aorta. European Journal of Pharmacology, 1989, 174, 279-282.	3.5	24
86	Chronic Activation of Heme Free Guanylate Cyclase Leads to Renal Protection in Dahl Salt-Sensitive Rats. PLoS ONE, 2015, 10, e0145048.	2.5	24
87	Generation and Characterization of a Stable Soluble Guanylate Cyclase-Overexpressing CHO Cell Line. Nitric Oxide - Biology and Chemistry, 1999, 3, 55-66.	2.7	23
88	The Rho kinase inhibitor azaindole-1 has long-acting vasodilator activity in the pulmonary vascular bed of the intact chest rat. Canadian Journal of Physiology and Pharmacology, 2012, 90, 825-835.	1.4	23
89	Î±1-A680T Variant in GUCY1A3 as a Candidate Conferring Protection From Pulmonary Hypertension Among Kyrgyz Highlanders. Circulation: Cardiovascular Genetics, 2014, 7, 920-929.	5.1	23
90	Novel, selective indole-based ECE inhibitors: Lead optimization via solid-phase and classical synthesis. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 4201-4205.	2.2	22

#	Article	IF	Citations
91	Measuring oxidative burden and predicting pharmacological response in coronary artery disease patients with a novel direct activator of haem-free/oxidised sGC. Atherosclerosis, 2011, 218, 431-434.	0.8	22
92	Soluble guanylate cyclase stimulators and their potential use: a patent review. Expert Opinion on Therapeutic Patents, 2021, 31, 203-222.	5.0	22
93	BAY 41-2272 inhibits the development of chronic hypoxic pulmonary hypertension in rats. European Journal of Pharmacology, 2010, 647, 147-154.	3.5	21
94	Novel soluble guanylyl cyclase stimulator BAY 41-2272 attenuates ischemia-reperfusion-induced lung injury. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2009, 296, L462-L469.	2.9	20
95	Prolonged Inhibition of Neutral Endopeptidase 24.11 by Sinorphan in Stroke-Prone Spontaneously Hypertensive Rats.. Hypertension Research, 1995, 18, 137-143.	2.7	19
96	Positive inotropic effect of exogenous and endogenous NO in hypertrophic rat hearts. British Journal of Pharmacology, 1997, 122, 813-820.	5.4	19
97	Tetrahydrobiopterin Protects Soluble Guanylate Cyclase against Oxidative Inactivation. Molecular Pharmacology, 2012, 82, 420-427.	2.3	19
98	Neutral Endopeptidase Inhibition Potentiates the Effects of Natriuretic Peptides in Renin Transgenic Rats.. Hypertension Research, 1996, 19, 229-238.	2.7	17
99	Preparation of heme-free soluble guanylate cyclase. Protein Expression and Purification, 2003, 31, 42-46.	1.3	16
100	Analysis of Erectile Responses to BAY 41-8543 and Muscarinic Receptor Stimulation in the Rat. Journal of Sexual Medicine, 2013, 10, 704-718.	0.6	16
101	Soluble CD154 Is a Unique Predictor of Nonfatal and Fatal Atherothrombotic Events in Patients Who Have End-Stage Renal Disease and Are on Hemodialysis. Journal of the American Society of Nephrology: JASN, 2007, 18, 1323-1330.	6.1	15
102	Acute hemodynamic response to single oral doses of BAY 60-4552, a soluble guanylate cyclase stimulator, in patients with biventricular heart failure. BMC Pharmacology, 2009, 9, .	0.4	15
103	Effects of Different Pulmonary Vasodilators on Arterial Saturation in a Model of Pulmonary Hypertension. PLoS ONE, 2013, 8, e73502.	2.5	15
104	The Soluble Guanylate Cyclase Activator BAY 58-2667 Protects against Morbidity and Mortality in Endotoxic Shock by Recoupling Organ Systems. PLoS ONE, 2013, 8, e72155.	2.5	15
105	The Selective Rho-kinase Inhibitor Azaindole-1 Has Long-lasting Erectile Activity in the Rat. Urology, 2013, 81, 465.e7-465.e14.	1.0	14
106	The soluble guanylate cyclase stimulator riociguat and the soluble guanylate cyclase activator cinaciguat exert no direct effects on contractility and relaxation of cardiac myocytes from normal rats. European Journal of Pharmacology, 2015, 767, 1-9.	3.5	14
107	Cardioprotective effects in aged spontaneously hypertensive rats due to chronic stimulation/activation of sGC without hypotension. BMC Pharmacology, 2009, 9, P29.	0.4	13
108	Runcaciguat, a novel soluble guanylate cyclase activator, shows renoprotection in hypertensive, diabetic, and metabolic preclinical models of chronic kidney disease. Naunyn-Schmiedeberg's Archives of Pharmacology, 2021, 394, 2363-2379.	3.0	13

#	Article	IF	Citations
109	Role of soluble guanylate cyclase in renal hemodynamics and autoregulation in the rat. American Journal of Physiology - Renal Physiology, 2014, 307, F1003-F1012.	2.7	12
110	Soluble Guanylate Cyclase Agonists Inhibit Expression and Procoagulant Activity of Tissue Factor. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 1578-1586.	2.4	11
111	Role of endogenous ANP on endocrine function investigated with a monoclonal antibody. Peptides, 1990, 11, 577-582.	2.4	10
112	New Antithrombotics with an Indazole Structure. Archiv Der Pharmazie, 2004, 337, 311-316.	4.1	9
113	Soluble Guanylate Cyclase. , 2010, , 301-326.		9
114	Identification of acidic heterocycle-substituted 1H-pyrazolo[3,4-b]pyridines as soluble guanylate cyclase stimulators. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 1197-1200.	2.2	9
115	Chronic intratracheal application of the soluble guanylyl cyclase stimulator BAY 41-8543 ameliorates experimental pulmonary hypertension. Oncotarget, 2017, 8, 29613-29624.	1.8	9
116	Selective Indole-Based ECE Inhibitors: Synthesis and Pharmacological Evaluation. ChemMedChem, 2006, 1, 96-105.	3.2	8
117	Structure/Activity Relationships of (M)ANT- and TNP-Nucleotides for Inhibition of Rat Soluble Guanylyl Cyclase Î±₁Î²₁. Molecular Pharmacology, 2014, 85, 598-607.	2.3	8
118	Receptor binding assay for nitric oxide- and heme-independent activators of soluble guanylate cyclase. Analytical Biochemistry, 2003, 314, 162-165.	2.4	7
119	Additional lack of iNOS attenuates diastolic dysfunction in aged ET-1 transgenic miceThis article is one of a selection of papers published in the special issue (part 1 of 2) on Forefronts in Endothelin.. Canadian Journal of Physiology and Pharmacology, 2008, 86, 353-357.	1.4	6
120	Gender-Dependent Impact of Risk Factors for Cardiovascular and Non-Cardiovascular Mortality in End-Stage Renal Disease Patients on Haemodialysis. Kidney and Blood Pressure Research, 2008, 31, 360-366.	2.0	6
121	Translational In Vivo Models for Cardiovascular Diseases. Handbook of Experimental Pharmacology, 2015, 232, 223-234.	1.8	6
122	Urinary cGMP predicts major adverse renal events in patients with mild renal impairment and/or diabetes mellitus before exposure to contrast medium. PLoS ONE, 2018, 13, e0195828.	2.5	6
123	Targeting heme-oxidized soluble guanylate cyclase with BAY 58-2667 in experimental heart failure. BMC Pharmacology, 2007, 7, .	0.4	5
124	Modulation of atrial natriuretic peptide-induced cGMP accumulation by [Arg8]vasopressin in the cultured renal epithelial cell line, LLC-PK1. European Journal of Pharmacology, 1988, 146, 341-344.	3.5	4
125	Effects of Nisoldipine on Atrial Natriuretic Peptides, Blood Pressure and Cardiac Hypertrophy in Dahl Rats. Clinical and Experimental Hypertension, 1990, 12, 1419-1436.	0.3	4
126	Inhaled NO and the guanylate cyclase stimulator Bay 41-2272 in oleic acid induced acute lung injury in rabbits. BMC Pharmacology, 2005, 5, P61.	0.4	4

#	Article	IF	Citations
127	NO-insensitive sGCbeta1 H105F knockin mice: if NO has no place to go. BMC Pharmacology, 2009, 9, .	0.4	4
128	Design and synthesis of the first NO- and haem-independent sGC activator BAY 58â€“2667 for the treatment of acute decompensated heart failure. BMC Pharmacology, 2007, 7, .	0.4	3
129	Influence of cinaciguat on gastrointestinal motility in apoâ€‹scp›sGC‹/scp› mice. Neurogastroenterology and Motility, 2014, 26, 1573-1585.	3.0	3
130	Antifibrotic effects of an sGC activator in rat models of liver fibrosis. BMC Pharmacology, 2005, 5, P24.	0.4	2
131	Beyond NO and heme: biochemical and pharmacological opportunities. BMC Pharmacology, 2005, 5, S18.	0.4	2
132	Oxidised sGC: a novel therapeutic target in the vasculature. BMC Pharmacology, 2007, 7, .	0.4	2
133	Receptor Binding Assay for NO-Independent Activators of Soluble Guanylate Cyclase. Methods in Molecular Biology, 2013, 1020, 205-214.	0.9	2
134	Potent cardiorenal actions in experimental heart failure with dual activation of soluble and particulate guanylate cyclases by bay 58-2667 and B-type natriuretic peptide: a novel therapeutic strategy. Journal of Cardiac Failure, 2004, 10, S90.	1.7	1
135	Co-activation of soluble and particulate guanylate cyclase by BAY 58-2667 and BNP enhances cardiorenal function in experimental heart failure. BMC Pharmacology, 2005, 5, 1.	0.4	1
136	Distinct molecular requirements for activation or stabilization of soluble guanylyl cyclase upon haem oxidation-induced degradation. BMC Pharmacology, 2009, 9, .	0.4	1
137	Additional stimulation of sGC on top of standard treatment with ARB`s may offer a new therapeutic approach for the treatment of diabetic nephropathy resistant to ARB treatment alone. BMC Pharmacology, 2011, 11, .	0.4	1
138	4-Phenyl-4H-pyrans as IKCa Channel Blockers.. ChemInform, 2003, 34, no.	0.0	0
139	Novel, Selective Indole-Based ECE Inhibitors: Lead Optimization via Solid-Phase and Classical Synthesis.. ChemInform, 2005, 36, no.	0.0	0
140	Formation of quasi-covalent sGC Î±1/Î²1-heterodimers by ODQ-induced oxidation of the prosthetic heme moiety. BMC Pharmacology, 2005, 5, P40.	0.4	0
141	Chronic activation of heme free soluble guanylate cyclase leads to cardio-renal protection in experimental hypertension. BMC Pharmacology & Toxicology, 2013, 14, .	2.4	0
142	Riociguat and cinaciguat exert no direct effects on contractility and relaxation of cardiac myocytes from normal rats. BMC Pharmacology & Toxicology, 2015, 16, .	2.4	0
143	Response to: Comment on â€œEffect of Riociguat and Sildenafil on Right Heart Remodeling and Function in Pressure Overload Induced Model of Pulmonary Arterial Bandingâ€. BioMed Research International, 2018, 2018, 1-2.	1.9	0
144	BAY 58â€2667, a Novel NOâ€Independent Activator of Soluble Guanylate Cyclase, Protects against Ischemia/Reperfusion Injury: Potential Role of Hydrogen Sulfide Signaling. FASEB Journal, 2010, 24, 787.4.	0.5	0

#	Article	IF	Citations
145	Sinorphan Improves Cardiac Structure and Function in Aged Stroke-Prone Spontaneously Hypertensive Rats. , 1995, , 70-79.		0